Table 2.
Emerging and recently established antimicrobials in the fight against Gram-negative antibiotic resistance. MDR, multi-drug resistant.
| Antimicrobial Agent | Targets | Approvals |
|---|---|---|
| Plazomicin | MDR E. coli, K. pneumoniae, P. mirabilis, A. baumannii | cUTI and pyelonephritis |
| Tigecycline | ESBL, CR Enterobacteriaceae, A. baumannii | cIAI and cSSI |
| Ceftolozane-tazobactam | MDR P. aeruginosa, Enterobacteriaceae spp. | cIAI, cUTI, HAP, and VAP |
| Aztreonam-avibactam | ESBL A baumannii, P. aeruginosa (Ambler Class A-D) | cIAI |
| Ceftazidime-avibactam | MDR Enterobacteriaceae spp., P. aeruginosa | cIAI, pyelonephritis, cUTI, HAP, and VAP |
| Imipenem-colistatin-relebactam | MDR K. pneumoniae, P. aeruginosa | cUTI, cIAI |
| Cefiderocol | MDR, CR P. aeruginosa, A. baumannii | cUTI, pyelonephritis |
| Eravacycline | ESBL, CR Enterobacteriaceae spp., MRSA, A. baumannii, VRE | cUTI, cIAI |
| Meropenem-vaborbactam | ESBL, CR Enterobacteriaceae (Ambler Class A and C) | cUTI, pyelonephritis, cIAI, HAP, VAP, and BSI |
ESBL—extended-spectrum βlactamase, CR—carbapenem resistant, VRE—vancomycin resistant Enterobacteriaceae, cUTI—complicated urinary tract infection, cIAI—complicated intrabdominal infections, HAP—hospital acquired pneumonia, VAP—ventilator associated pneumonia, BSI–bloodstream infections.